Search Results

1 - 10 of 147 items :

  • "prostate cancer" x
  • Internal Medicine x
Clear All
Left Supraclavicular Lymphadenopathy as the Only Clinical Presentation of Prostate Cancer: A Case Report

, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European journal of cancer. 2013; 49(6):1374-403. 4. Venable DD, Hastings D, Misra RP. Unusual metastatic patterns of prostate adenocarcinoma. The Journal of urology. 1983; 130(5):980-5. 5. MINTZ ER, SMITH GG. Autopsy findings in 100 cases of prostatic cancer. New England Journal of Medicine. 1934; 211(11):479-87. 6. Flocks RH, Boatman DL. Incidence of head and neck metastases from genito urinary neoplasms

Open access
Multiparametric MRI - local staging of prostate cancer and beyond

Introduction Accurate staging of prostate cancer is essential to inform prognosis and to stratify patients for appropriate management. MRI affords excellent soft tissue differentiation making it the most accurate modality for preoperative local T-staging of prostate cancer. 1 According to European Association of Urology (EAU) guidelines, local staging investigations are only indicated for intermediate and high-risk patient groups. 1 The high accuracy of multiparametric MRI (mpMRI) for detection of index lesions can aid T-staging, and can also identify

Open access
The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients

Introduction Conventional clinical parameters alone are inadequate for differentiating indolent and aggressive prostate cancer. Therefore, molecular biomarkers are needed to better define prognosis of prostate cancer patients. Neuroendocrine markers could be used to detect particularly aggressive variants of prostate cancer. Typical markers used to identify neuroendocrine differentiation (NED) in tumor tissue are neuron specific enolase (NSE), chromogranin A (CgA) and synaptophysin (Syp). 1 - 3 Neuroendocrine differentiation, measured by one or more of

Open access
Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel

Disclosure: B. Seruga received honoraria for his advisory role at Sanofi. All remaining authors have declared no conflicts of interest. References 1. Jespersen CG, Norgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014; 65: 704-9. 2. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin

Open access
Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness

References Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60 : 277-300. Brawley OW, Ankerst DP, Thompson IM. Screening prostate cancer. CA Cancer Clin 2009; 59 : 264-73. Albersen PC. A challenge to contemporary management of prostate cancer. Nat Clin Pract Urol 2009; 6 : 12-3. Avazpour I, Roslan RE, Bayat P, Saripan MI, Nordin AJ, Abdullah RSAR. Segmenting CT images of bronchogenic carcinoma with bone metastases using

Open access
Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey

References 1. Balogova S, Kobetz A, Huchet V, Michaud L, Kerrou K, Paycha F, et al. Évolution de la demande des examens de médecine nucléaire pour cancer de la prostate depuis l’enregistrement de la fluorocholine (18F): analyse sur deux ans à l’hôpital Tenon. Méd Nucl 2012; 36: 363-70. 2. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV, et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012; 10: 1081-7. 3. Even-Sapir E, Metser

Open access
A comparison of virtual touch tissue quantification and digital rectal examination for discrimination between prostate cancer and benign prostatic hyperplasia

References Milecki P, Martenka P, Antczak A, Kwias Z. Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art. Cancer Manag Res 2010; 2 : 243-53. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010. CA Cancer J Clin 2010; 60 : 70-98. Brawley OW, Ankerst DP, Thompson IM. Screening for Prostate Cancer. CA Cancer J Clin 2009; 59 : 264

Open access
Obstructive urination problems after high-dose-rate brachytherapy boost treatment for prostate cancer are avoidable

Introduction Several modes of radical local treatment are on disposal for patients with localized or locally advanced prostate cancer. Beside radical prostatectomy, radical irradiation in the form of external beam radiotherapy (EBRT), and permanent brachytherapy (PB) or high-dose-rate brachytherapy (HDRB) are established ways of treatment. Both treatment modalities should be considered as equally effective in the absence of randomized trials. Similar consideration should also be given to different ways of radiation treatment. 1 , 2 When radiation therapy

Open access
Interdisciplinary consensus statement on indication and application of a hydrogel spacer for prostate radiotherapy based on experience in more than 250 patients

Background Dose escalated intensity-modulated radiation treatment (IMRT with radiation doses ≥ 76 Gy) is a highly effective, curative treatment option for localized prostate cancer. Biochemical control is directly related to radiation dose with a dose effect per each additional Gy. 1 For example, escalation from 70 to 80 Gy is connected with a 15% increase in PSA control. This dose effect is described for all risk groups. However, an increased radiation dose is also associated with rising levels of grade ≥ 2 acute and chronic toxicity. 1 Lower

Open access
Increased late urinary toxicity with whole pelvic radiotherapy after prostatectomy

References Thompson IM, Tangen CM, Paradelo J, Lucia S, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer. JAMA 2006; 296: 2329-35. Bolla M, van Poppel H, Colette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 52-8. Wiegel T, Bottke D, Willich H, Piechota H, Souchon R, Stoeckle M, et al. Phase III results of

Open access